Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04053387 · ClinicalTrials.gov registry record · Phase 3
Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)
A Phase 3 study, sponsored by Organon and.
- Completed
- Registry status
- Phase 3
- Development phase
- 763
- Enrollment target
NCT04053387 is a Phase 3 study that has completed, run by Organon and. The registered enrollment target is 763 participants.
The verdict
NCT04053387, a Phase 3 study, has completed, sponsored by Organon and.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 763 participants
- Enrollment target
Study Summary
This is a long-term, open-label, multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in adults with plaque psoriasis. Subjects in this study completed treatment in 1 of 2 Phase 3 pivotal efficacy and safety studies (Study DMVT-505-3001 or Study DMVT-505-3002). This study will consist of up to 40 weeks of treatment and a 4-week safety follow-up period.
Interventions
- DRUG tapinarof cream, 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 763 participants |
| Start Date | 2019-08-13 |
| Est. Completion | 2021-04-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04053387
The ClinicalTrials.gov registry entry for NCT04053387 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 763 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Organon and, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tapinarof cream, 1% is the first listed.
NCT04053387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04053387 about?
NCT04053387 is a clinical study titled "Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)". This is a long-term, open-label, multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in adults with plaque psoriasis. Subjects in this study completed treatment in 1 of 2 Phase 3 pivotal efficacy and safety studies (Study DMVT-505-3001 or Study DMVT-505-3002). This ...
What is the current status of trial NCT04053387?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 763 participants. The study started on 2019-08-13. Estimated completion is 2021-04-06.
What interventions are being tested in trial NCT04053387?
The interventions under investigation include: tapinarof cream, 1% (DRUG).
Who is sponsoring clinical trial NCT04053387?
This trial is sponsored by Organon and, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.